Multidrug / rifampicin-resistant tuberculosis
MDR/RR-TB · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
MDR-TB is resistant to at least isoniazid and rifampicin (rifampicin resistance alone, RR-TB, is managed similarly). Modern all-oral regimens built on bedaquiline, pretomanid and linezolid have transformed outcomes and shortened treatment.
Red flags
- QTc prolongation on bedaquiline/fluoroquinolone/clofazimine
- Linezolid myelosuppression or peripheral/optic neuropathy
- Treatment failure or additional fluoroquinolone resistance (pre-XDR/XDR)
- Clinical deterioration or massive haemoptysis
Assessment
Differential diagnosis
- Drug-sensitive TB with treatment failure from non-adherence
- Non-tuberculous mycobacterial disease
- Laboratory error / mixed infection
- Reinfection with a resistant strain
Investigations
- Rapid molecular resistance testing (Xpert MTB/RIF, line-probe assays, targeted NGS)
- Phenotypic drug-susceptibility testing including fluoroquinolones and bedaquiline
- Culture for monitoring conversion
- Baseline ECG (QTc), LFTs, renal function, FBC, visual acuity, TSH
- HIV test and contact tracing
Management
- Confirm rifampicin/multidrug resistance with rapid molecular testing
- Obtain extended drug-susceptibility testing including fluoroquinolones
- Refer to a specialist drug-resistant TB service and notify public health
- Implement strict airborne infection control
- Baseline ECG, bloods, vision and thyroid function before therapy
- Construct an all-oral regimen (e.g. BPaLM) according to current WHO guidance and susceptibilities
- Monitor QTc, haematology, neuropathy and visual/auditory function during treatment
- Support adherence with patient-centred directly/video-observed therapy
- Track culture conversion to guide duration
- Manage adverse events proactively and avoid injectable agents where oral options exist
Drugs & doses
Bedaquiline 400 mg PO once daily x2 weeks then 200 mg three times weekly (or per current labelling)
Pretomanid 200 mg PO once daily
Linezolid 600 mg PO once daily (dose-adjusted for toxicity)
Moxifloxacin 400 mg PO once daily (BPaLM regimen adds moxifloxacin)
Clofazimine / cycloserine as components of longer individualised regimens
Disposition
Specialist drug-resistant TB unit; public-health notification; supervised adherence and toxicity monitoring; isolation while infectious.
Complications & pitfalls
- QT-related arrhythmia
- Linezolid neuropathy and cytopenias
- Progression to extensively drug-resistant TB
- Chronic lung damage and respiratory failure
- Transmission to contacts
Exam pearls
- All-oral BPaLM/BPaL regimens have replaced long injectable-based regimens for most RR/MDR-TB
- Serial ECG monitoring is essential with QT-prolonging combinations
- Never treat resistant TB outside a specialist service
- Culture conversion is the key monitoring endpoint for response
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.